TODD GATES: Open Payments
NPI 1992702260 · WEST MELBOURNE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$274,064 in 400 payments from 12 companies in 2025. Trend: 2023 $294,997 · 2024 $190,734 · 2025 $274,064
Speaker / faculty: $187,937Travel & lodging: $31,952Honoraria: $26,175Consulting: $20,615Food & beverage: $7,385
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 192 | $148,755 |
| E.R. Squibb & Sons, L.L.C. | 54 | $51,319 |
| Neurocrine BioSciences, Inc. | 49 | $38,593 |
| Axsome Therapeutics, Inc. | 36 | $28,884 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 37 | $5,873 |
| Alkermes, Inc. | 8 | $158 |
| Vanda Pharmaceuticals Inc. | 9 | $137 |
| Otsuka America Pharmaceutical, Inc. | 5 | $115 |
| Luye Pharma (USA) Ltd. | 3 | $82 |
| Teva Pharmaceuticals USA, Inc. | 4 | $79 |
Products named: VRAYLAR, COBENFY, INGREZZA, Auvelity, CAPLYTA, ARISTADA, FANAPT, ABILIFY ASIMTUFII.
Industry payments across FL — which companies pay providers there.
